PR200 targeted commercial launch date

PR200 enters clinic, first subject dosed

Precision IBD acquires Prometheus Labs to form Prometheus Biosciences

Precision IBD nominates first clinical candidate mAb, PR200

Prometheus launches Monitr™

Precision IBD is formed

Prometheus launches Anser®

Prometheus Labs launches 1^st diagnostic, pANCA

Prometheus Labs is formed

1st sample collected. The beginning of our GI Medicines Platform